OptiNose (OPTN) Q2 2024 earnings summary

Executive summary

• XHANCE received FDA approval for chronic sinusitis (including chronic rhinosinusitis without nasal polyps) in March 2024, expanding its addressable market by up to 10x and making it the first and only approved drug for this indication.

• The company relaunched XHANCE, realigned sales territories, and transitioned to a central pharmacy hub model to support anticipated growth, with early launch results showing positive prescription growth among new and infrequent prescribers.

• Achieved significant improvements in insurance coverage, including preferred Tier 2 status on major Express Scripts formularies, expanding access to over 24 million covered lives.

• A $55–$55.3 million registered direct offering in May 2024 and debt agreement revisions provide sufficient cash to fund operations and service debt through 2025.

• Commercial efforts focused on prescriber education and outreach, targeting ENT, allergy, and primary care physicians, with more than half of sales calls directed at new or infrequent prescribers.

Financial highlights

• Q2 2024 XHANCE net revenue was $20.5 million, up 5% year-over-year; first half 2024 net revenue was $35.4 million, up 13% year-over-year.

• Q2 2024 average net revenue per prescription was $309, a 44% increase from Q2 2023; first half 2024 average was $269, up 51% year-over-year.

• Q2 2024 operating expenses (SG&A plus R&D) were $25.1 million, up from $21.1 million in Q2 2023; first half 2024 operating expenses were $46.8 million.

• Net loss for Q2 2024 was $7.6 million ($0.07 per diluted share); six-month net loss was $21.6 million ($0.17 per diluted share).

• Cash and cash equivalents as of June 30, 2024 were $91.4 million; debt was $130 million.

Outlook and guidance

• Full-year 2024 XHANCE net revenue guidance narrowed to $85–$90 million, representing 20%–27% growth over 2023.

• Average net revenue per prescription for 2024 expected to exceed $250, up at least 20% from 2023.

• 2024 GAAP operating expenses projected at $95–$101 million, including ~$6 million in stock-based compensation.

• Positive operating income projected for full year 2025; cash runway expected through 2025.

• Current sales footprint and incremental investment expected to drive peak net revenue of at least $300 million.